B-Cell Repletion Common With MS Drug, but No Symptom Worseni

Although some repletion of B cells occurs with the B-cell depleting MS drug ocrelizumab, the effect does not appear to be associated with symptom worsening or a 'wearing off' effect.

Related Keywords

Florida , United States , Orlando , Massachusetts , Scottd Newsome , Joshuad Katz , , Johns Hopkins University Neurosciences Consultation , Consortium Of Multiple Sclerosis Centers , Elliot Lewis Center , Infusion Center , Multiple Sclerosis Care , Medscape Medical , Multiple Sclerosis Centers , Expanded Disability Status Scale , Neurological Disorders , Medscape Medical News , Johns Hopkins University , Neurosciences Consultation , Multiple Sclerosis Ms , Multiple Sclerosis , Us , Spasticity , Fatigue , Depression , Disability , Dizziness , Magnetic Resonance Imaging Mri , Magnetic Resonance Imaging , Ri , Maging Magnetic Resonance , Spain , Pain Management , Clinical Research , Clinical Trials , Linical Studies , Biologic Therapy , Monoclonal Antibody , Etuximab , Ituximab , Body Mass Index Bmi ,